Cargando…

Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine

Refractory chronic migraine is a disabling disorder impacting quality of life. BOTOX(®) (Onabotulinumtoxin A) is approved as a prophylactic treatment of chronic migraine in patients unresponsive to at least three prior preventive treatments. The objective of this study was to determine the prophylac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ion, Ioana, Renard, Dimitri, Le Floch, Anne, De Verdal, Marie, Bouly, Stephane, Wacongne, Anne, Lozza, Alessandro, Castelnovo, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024863/
https://www.ncbi.nlm.nih.gov/pubmed/29857565
http://dx.doi.org/10.3390/toxins10060221
_version_ 1783336150876815360
author Ion, Ioana
Renard, Dimitri
Le Floch, Anne
De Verdal, Marie
Bouly, Stephane
Wacongne, Anne
Lozza, Alessandro
Castelnovo, Giovanni
author_facet Ion, Ioana
Renard, Dimitri
Le Floch, Anne
De Verdal, Marie
Bouly, Stephane
Wacongne, Anne
Lozza, Alessandro
Castelnovo, Giovanni
author_sort Ion, Ioana
collection PubMed
description Refractory chronic migraine is a disabling disorder impacting quality of life. BOTOX(®) (Onabotulinumtoxin A) is approved as a prophylactic treatment of chronic migraine in patients unresponsive to at least three prior preventive treatments. The objective of this study was to determine the prophylactic effect of 145 U XEOMIN(®) (Incobotulinumtoxin A) injected at 31 specific sites in adult patients with refractory chronic migraine. Sixty-one patients (8 men and 53 women, mean age 50) with migraine were recruited, including 20 patients with isolated chronic migraine, 18 patients with chronic migraine associating tension-type headache, 12 patients with migraine associating medication overuse headache, and 11 patients with episodic disabling migraine. The mean number of injections and duration of treatment per patient was 3.5 (range 2–13) and 21 (6–68) months, respectively. From baseline to first injection, 44 patients (73%) had >50% reduction in frequency of migraine episodes, 29 patients (48%) showed >50% reduction in number of headache days, and 28 patients (46%) had a >50% reduction in drug intake. Stable response for all three parameters was observed after the last injection. XEOMIN(®) thus seems to represent an effective and sustained prophylactic treatment of chronic migraine.
format Online
Article
Text
id pubmed-6024863
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60248632018-07-09 Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine Ion, Ioana Renard, Dimitri Le Floch, Anne De Verdal, Marie Bouly, Stephane Wacongne, Anne Lozza, Alessandro Castelnovo, Giovanni Toxins (Basel) Article Refractory chronic migraine is a disabling disorder impacting quality of life. BOTOX(®) (Onabotulinumtoxin A) is approved as a prophylactic treatment of chronic migraine in patients unresponsive to at least three prior preventive treatments. The objective of this study was to determine the prophylactic effect of 145 U XEOMIN(®) (Incobotulinumtoxin A) injected at 31 specific sites in adult patients with refractory chronic migraine. Sixty-one patients (8 men and 53 women, mean age 50) with migraine were recruited, including 20 patients with isolated chronic migraine, 18 patients with chronic migraine associating tension-type headache, 12 patients with migraine associating medication overuse headache, and 11 patients with episodic disabling migraine. The mean number of injections and duration of treatment per patient was 3.5 (range 2–13) and 21 (6–68) months, respectively. From baseline to first injection, 44 patients (73%) had >50% reduction in frequency of migraine episodes, 29 patients (48%) showed >50% reduction in number of headache days, and 28 patients (46%) had a >50% reduction in drug intake. Stable response for all three parameters was observed after the last injection. XEOMIN(®) thus seems to represent an effective and sustained prophylactic treatment of chronic migraine. MDPI 2018-06-01 /pmc/articles/PMC6024863/ /pubmed/29857565 http://dx.doi.org/10.3390/toxins10060221 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ion, Ioana
Renard, Dimitri
Le Floch, Anne
De Verdal, Marie
Bouly, Stephane
Wacongne, Anne
Lozza, Alessandro
Castelnovo, Giovanni
Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine
title Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine
title_full Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine
title_fullStr Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine
title_full_unstemmed Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine
title_short Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN(®)) Botulinum Toxin in Chronic Refractory Migraine
title_sort monocentric prospective study into the sustained effect of incobotulinumtoxin a (xeomin(®)) botulinum toxin in chronic refractory migraine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024863/
https://www.ncbi.nlm.nih.gov/pubmed/29857565
http://dx.doi.org/10.3390/toxins10060221
work_keys_str_mv AT ionioana monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine
AT renarddimitri monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine
AT leflochanne monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine
AT deverdalmarie monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine
AT boulystephane monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine
AT wacongneanne monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine
AT lozzaalessandro monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine
AT castelnovogiovanni monocentricprospectivestudyintothesustainedeffectofincobotulinumtoxinaxeominbotulinumtoxininchronicrefractorymigraine